Implications of ICU triage decisions on patient mortality: a cost-effectiveness analysis by Edbrooke, DL et al.
RESEARCH Open Access
Implications of ICU triage decisions on patient
mortality: a cost-effectiveness analysis
David L Edbrooke1,2, Cosetta Minelli2,3, Gary H Mills2,4*, Gaetano Iapichino5, Angelo Pezzi5, Davide Corbella5,
Philip Jacobs6, Anne Lippert7, Joergen Wiis7, Antonio Pesenti8, Nicolo Patroniti8, Romain Pirracchio9, Didier Payen9,
Gabriel Gurman10, Jan Bakker11, Jozef Kesecioglu12, Chris Hargreaves13, Simon L Cohen14, Mario Baras15,
Antonio Artigas16, Charles L Sprung17
Abstract
Introduction: Intensive care is generally regarded as expensive, and as a result beds are limited. This has raised
serious questions about rationing when there are insufficient beds for all those referred. However, the evidence for
the cost effectiveness of intensive care is weak and the work that does exist usually assumes that those who are
not admitted do not survive, which is not always the case. Randomised studies of the effectiveness of intensive
care are difficult to justify on ethical grounds; therefore, this observational study examined the cost effectiveness of
ICU admission by comparing patients who were accepted into ICU after ICU triage to those who were not
accepted, while attempting to adjust such comparison for confounding factors.
Methods: This multi-centre observational cohort study involved 11 hospitals in 7 EU countries and was designed
to assess the cost effectiveness of admission to intensive care after ICU triage. A total of 7,659 consecutive patients
referred to the intensive care unit (ICU) were divided into those accepted for admission and those not accepted.
The two groups were compared in terms of cost and mortality using multilevel regression models to account for
differences across centres, and after adjusting for age, Karnofsky score and indication for ICU admission. The
analyses were also stratified by categories of Simplified Acute Physiology Score (SAPS) II predicted mortality (< 5%,
5% to 40% and >40%). Cost effectiveness was evaluated as cost per life saved and cost per life-year saved.
Results: Admission to ICU produced a relative reduction in mortality risk, expressed as odds ratio, of 0.70 (0.52 to
0.94) at 28 days. When stratified by predicted mortality, the odds ratio was 1.49 (0.79 to 2.81), 0.7 (0.51 to 0.97) and
0.55 (0.37 to 0.83) for <5%, 5% to 40% and >40% predicted mortality, respectively. Average cost per life saved for
all patients was $103,771 (€82,358) and cost per life-year saved was $7,065 (€5,607). These figures decreased
substantially for patients with predicted mortality higher than 40%, $60,046 (€47,656) and $4,088 (€3,244),
respectively. Results were very similar when considering three-month mortality. Sensitivity analyses performed to
assess the robustness of the results provided findings similar to the main analyses.
Conclusions: Not only does ICU appear to produce an improvement in survival, but the cost per life saved falls for
patients with greater severity of illness. This suggests that intensive care is similarly cost effective to other therapies
that are generally regarded as essential.
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Introduction
Intensive care is generally regarded as expensive, with
historical reports of the average cost per patient-day
ranging from £858 to 1,185 in the UK [1]. Attempts to
limit resources have raised the question of who gets
admitted to ICU when there are insufficient beds for all
referred patients [2,3]. This has raised serious ethical
concerns worldwide due to the implications of ICU
rationing [3,4] on patient outcomes [5,6]. However, the
evidence for the cost effectiveness of intensive care is
currently weak. Ideally a randomised study would
answer this question. However, randomised studies of
the cost effectiveness of intensive care are difficult to
implement and justify ethically. Previous cost effective-
ness evaluations [7-10] have generally assumed patients
not admitted to intensive care die, which is not always
the case [5,6]. If intensive care is to be measured against
other forms of therapy, all of which are competing for
scarce resources, some attempt at a cost-effectiveness
analysis of admission to intensive care is urgently
needed.
The present study is a cost-effectiveness analysis of
ICU admission compared with ward care for patients
referred for admission to ICU, in which clinical out-
comes (28-day and 3-month mortality) and resource use
were measured for both settings.
Materials and methods
The present cost-effectiveness analysis is part of the
Elderly in European Intensive Care Units (ELDICUS)
project (QLK6-CT-2002-00251 EU FP5), a prospective
multicentre cohort study investigating ICU triage deci-
sions. The study received ethics committee approval
from the institutional review board in all centres and
the need for individual patient consent was waived.
Patients referred to the intensive care unit (ICU) were
divided into those accepted for admission and those not
accepted. The two groups were then compared in terms
of mortality and cost as a whole and also in categories
of Simplified Acute Physiology Score (SAPS) II pre-
dicted mortality.
Study population
Consecutive adult patients (older than 18 years) referred
for admission to ICU were recruited in 11 hospitals
from 7 European Union or associated countries (Den-
mark, France, Israel, Italy, Netherlands, Spain and the
UK), between September 2003 and March 2005. There
was no upper limit on age. This was an observational
study and no attempt was made to influence decisions
to admit or not admit patients to ICU. Patients were
referred to ICU by doctors in the emergency depart-
ment, medical ward, surgical ward or operating room.
Patients were excluded if they were referred to ICU for
consultation only or from other ICUs as well as inter-
mediate (high dependency) units in the same hospital.
For patients with more than one ICU triage during the
same hospital stay, only the first triage was considered
in the present analyses.
Effect of ICU admission on patient mortality
The effectiveness of ICU admission was evaluated by
comparing the 28-day mortality for patients accepted in
ICU with that of patients not accepted and treated in
the ward. Three-month mortality was also evaluated as
a secondary outcome. Although hospital mortality was
also available, we did not use this outcome measure
since this varies widely across centres and countries as a
result of different policies for hospital discharge.
The case mix of patients accepted in ICU is likely to
differ in terms of severity and prognosis from that of
patients refused, and, therefore, analyses were adjusted
for possible confounders.
Possible confounding variables were selected through
backward stepwise procedure, and included; age; Kar-
nofsky performance status (a marker of chronic health);
and indication for referral to ICU (treatment or observa-
tion). Since the observed effect on mortality of ICU
admission varied with the severity of illness (as mea-
sured by SAPS II), the analyses were stratified by cate-
gories of predicted mortality, calculated from the SAPS
II score [11].
Costs
Cost of ICU admission was evaluated by comparing the
total hospital cost per patient for patients accepted to
the ICU against the total cost for patients not accepted
and treated on the ward. For patients accepted to ICU,
the total cost was defined as the cost of the ICU stay,
plus the ward stay cost after ICU discharge. The daily
cost per patient for both ICU and ward was calculated
for each participating hospital using a top-down
approach, based on the cost-block method [1]. Although
this approach has been developed for use in the ICU, it
has also been used to calculate ward costs for consis-
tency and in the absence of any other accepted method
[12]. The cost-block method derives an average daily
cost per patient from the total annual cost of the unit.
The total annual cost is estimated as the sum of the
main cost determinants, or “cost-blocks”, which include;
consumables (drugs, nutritional products, blood pro-
ducts and disposables); clinical support services defined
as services essential to the ICU but not provided within
the ICU (laboratory, radiology and physiotherapy); and
ICU staff (doctors, junior and senior, and nurses). In the
UK, cost-blocks have been shown to account for 85% of
the total annual ICU cost, with the remaining 15%,
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described as “overheads”, including maintenance costs of
the hospital and ICU [1]. These overheads of 15% were
thus added to the calculated costs. Data on cost-blocks
were collected using the cost-block questionnaire [1]. In
each hospital, the cost-block questionnaire was com-
pleted by the participating ICU and by one surgical and
one medical ward. The annual ward cost was defined as
the average of the costs of the two wards.
Daily costs per patient were calculated based on the
annual cost and the number of beds, assuming an occu-
pancy rate of 100%. In fact, a large part of the total cost
of care is represented by staff cost, which does not nor-
mally depend on occupancy.
Between countries, costs were standardised to a com-
mon currency using Purchasing Power Parities (PPPs)
rather than exchange rates, as the latter were designed to
compare costs in financial markets which, unlike health
service costs, change rapidly. The World Health Organi-
sation (WHO) PPPs were used because they consider
health costs, are reported in many countries and are fre-
quently updated [13]. The numeraire currency is the
International Dollar, a theoretical currency based on what
can be bought in each country with the US dollar [14]. In
practice the International Dollar corresponds to the US
Dollar and so the International $ is simply referred to as
$ in this study. To aid interpretation in Europe we have
also converted our results to Euros using the Dollar to
Euro conversion rate in place at the end of the study;
that is, $1.26 is equivalent to €1.00. We have also applied
this conversion rate to other papers quoted in our manu-
script where a Euro figure was not available.
Cost estimates for the cost-effectiveness analyses were
adjusted for the same covariates selected in the analysis
of effectiveness (age, Karnofsky performance status, indi-
cation for referral to ICU), and cost-effectiveness ana-
lyses were stratified by severity of illness (predicted
mortality based on SAPS II).
Cost effectiveness of ICU admission
The cost effectiveness of ICU admission, compared with
ward care, after ICU triage was evaluated using two mea-
sures; cost per life saved and cost per life-year saved.
These were calculated at 28 days and 3 months after dis-
charge for all admissions and represent the cost over and
above ward care in relation to the benefit accrued.
Cost per life saved
The cost per life saved, or incremental cost-effectiveness
ratio, is the difference in cost divided by the difference
in mortality rates (absolute risk reduction), with the lat-
ter being calculated from the odds ratio derived from
the adjusted analyses (see Additional file 1).
Cost per life-year saved
The calculation of a cost per life-year saved requires an
estimate of the life expectancy for survivors (see
Additional file 1), information which was obtained from
published data. Life expectancy of ICU survivors differs
from that of the general population only for the first two
[15,16] to four [17,18] years after hospital discharge.
Thus, a hypothetical value of life expectancy was assigned
to each patient using general population estimates speci-
fic for age, gender and country, after accounting for
excess mortality in the first four years after hospital dis-
charge (see Additional file 1). Figures on life expectancy
in the general population were obtained from EURO-
STAT [19] for European countries, and from the U.S
Census Bureau - International Data Base [20] for Israel.
Sensitivity analyses
A number of sensitivity analyses have been performed to
assess the robustness of the results of our study, where
we varied; 1) inclusion of individual centres in the analy-
sis (excluding the two centres with the most extreme
results for effectiveness); 2) inclusion of patients in the
analysis, according to the reason for ICU triage (ICU
treatment/observation); 3) method used to estimate ICU
daily costs.
Excluding centres with extreme results
Although in the main cost-effectiveness analyses we
accounted for the variability across centres by use of
multilevel models for effectiveness and cost estimates, it
is possible that the overall results might have been dri-
ven by one or two centres with extreme results. In
order to evaluate the robustness of our findings, we per-
formed a sensitivity analyses where we excluded the two
centres with the most extreme results, one suggesting a
very large benefit of ICU admission (odds ratio of 0.3;
95% CI: 0.1 to 0.4) and one suggesting harm (1.2; 95%
CI: 0.8 to 1.8), compared with the others.
Excluding problematic categories of patients
Although we adjusted the analyses for potential con-
founding factors and for study centre, still the presence
of some categories of patients in our study population
could have biased the results. Such patients include
those referred to ICU only for observation and those
admitted to ICU even if affected by terminal cancer. In
both situations, the policy for ICU admission varies
widely across centres, heavily depending on the avail-
ability of high dependency units or intermediate care
units in the same hospital, as well as on cultural or reli-
gious factors. Therefore, we performed sensitivity ana-
lyses where we excluded: 1) patients referred to ICU for
observation, thus only considering patients who had
been triaged for ICU treatment; 2) patients with term-
inal cancer. Because direct information on the presence
of terminal cancer was not available, we used a diagno-
sis of cancer accompanied with a Karnofsky score ≤50
(50 = “requires considerable assistance and frequent
medical care”) as a proxy for terminal cancer.
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Estimating ICU daily cost based on level of care
In the ICU, unlike the ward, patients receive very differ-
ent levels of nursing care. Nurses represent the largest
cost component in ICU, so that different levels of nur-
sing care translate into a high variability of daily cost
per patient [1]. To account for differences in levels of
nursing care, a sensitivity analysis based on a modified
cost-block approach for the estimation of ICU daily cost
per patient was performed, where the nursing cost was
calculated based on information on daily specific proce-
dures performed on the patient (see Additional file 1).
Estimates of nursing cost per patient-day calculated
using this method were entered into the cost block cal-
culations in place of the average nurse cost derived
from the annual nurse cost. This sensitivity analysis
could only be performed on a subset of 37% of the
patients admitted to ICU, for which information on
daily procedures was available.
Statistical analyses
Descriptive statistics utilised mean with standard devia-
tion and median with interquartile range (IQR) as appro-
priate. Multilevel models were used for both effectiveness
and cost analyses in order to account for the clustering
effect induced by recruitment at multiple centres, namely
cluster logistic regression and random effects linear
regression, respectively. Selection of covariates to include
in the regression models was performed based on
adjusted R-square, using backward stepwise regression.
The 95% confidence intervals for the estimates of the
cost per life saved and cost per life-year saved were
obtained using nonparametric bootstrap with replacement
[21]. All analyses were performed using Stata 9.1 software
(StataCorp. 2005. Stata Statistical Software: Release 9.
College Station, TX, USA: StataCorp LP).
Results
Characteristics of the study population
A total of 7,449 patients were included in the study.
Baseline characteristics for the whole study population
and separately for patients accepted and not accepted in
ICU are reported in Table 1. The two groups differed in
terms of age, Karnofsky score and predicted mortality
based on SAPSII, with patients not accepted to ICU
being older, with worse chronic health and more
severely ill. The analyses were, therefore, adjusted for
these confounders. There was also variation in referral
site, with rate of acceptance being much lower for emer-
gency room and much higher for the recovery room/
operating room. Similar differences were observed for
type of referral, with a much higher acceptance rate for
surgery compared with medical referrals. In the overall
sample, 15% of the patients were refused admission,
although ICU admission refusal rates varied widely
across centres, (2%, 5%, 10%, 11%, 13%, 18%, 18%, 25%,
27%, 28%, 48%), partly due to differences in case-mix.
Effect of ICU admission on patient mortality
Results on length of stay (LOS) and mortality are
reported in Table 2. Total hospital length of stay was
higher in the accepted group (19.3 vs. 14.7; P < 0.001).
For patients accepted to the ICU, the mean ICU LOS
was 5.7 days (Standard Deviation 11.1), while the later
ward LOS for these patients was 13.6 (23.6).
The mortality at both 28 days and 3 months was sig-
nificantly lower in the group admitted to the ICU. The
results of the adjusted analyses of mortality are reported
in Table 3. For mortality at 28 days, the estimate of the
risk of death in accepted versus non-accepted patients,
expressed in terms of odds ratio, was 0.7 (95% CI: 0.5 to
0.9; P = 0.017). The odds ratio increasingly favoured
intensive care admission as predicted mortality rose. In
patients with >40% predicted mortality the odds ratio
reached 0.6 (95% CI: 0.4 to 0.8; P = 0.004).
Costs
Total cost per hospital stay for patients accepted and
not accepted into ICU are reported in Table 2. The
mean daily cost per patient was $371 (€294) (95% CI:
$368 (€292) to $374 (€296)) for the ward stay and
$1,339 (€1,063) (95% CI: $1,334 (€1,059) to $1,343
(€1,066)) for the ICU stay.
After adjusting the analyses of costs for the same vari-
ables, the estimated difference in costs per patient
between accepted and not accepted was $6,156 (€4,886)
(95% CI: $5,028 (€3,990) to $7,283 (€5,780)).
Cost effectiveness of ICU admission
Based on the results of the adjusted analyses of 28-day
mortality and costs, the estimate of cost per life saved was
$103,771 (€82,358) (95% CI: $56,855 (€45,123) to $150,687
(€119,593)). The values of life expectancy assigned to each
patient gave an average life expectancy in our population
of 14.7 years after hospital discharge. Using this average
figure, a cost per life-year saved of $7,065 (€5,607) (95%
CI: $3,871 (€3,072) to $10,259 (€8,142)) was obtained. The
cost effectiveness of ICU admission increased with
increasing predicted mortality (Table 4).
Estimates of cost per life saved and cost per life-year
saved were similar when considering mortality at three
months, $103,418 (€82,078) (95% CI: $44,198 (€35,078)
to $162,639 (€129,079)) and $7,041 (€5,588) (95% CI:
$3,009 (€2,388) to $11,073 (€8,788)), respectively.
Sensitivity analyses
Excluding centres with extreme results
In this sensitivity analysis we excluded 1,471 patients
(19.7% of the whole sample) from two centres, which
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showed the most extreme positive and negative mor-
tality results. Results of the analysis for 28-day mortal-
ity were a cost per life saved of $119,301 (€94,683)
($26,581 (€21,096) to $212,020 (€168,270)) and a cost
Table 1 Baseline characteristics of the study sample
Results Overall population
(n = 7,449)
Accepted
(n = 6,312)
Rejected
(n = 1,137)
P-value
Age
Mean (SD) 60.3 (18.0) 59.3 (18.0) 65.7 (17.3) < 0.001a
≥70 (%) 38 36 51 < 0.001b
Males (%) 58 58 57 0.56 b
Karnofsky score
Median (IQR) 80 (70 to 90) 80 (70 to 90) 80 (60 to 90) < 0.001c
≤50d (%) 14 12 24 < 0.001b
Predicted mortality (based on SAPS II)
< 5 (%) 29 30 20 < 0.001b
5 to 40 (%) 54 52 60
> 40 (%) 18 17 20
Referral site (%) < 0.001b
Operating/
Recovery room
34 39 5
A&E 29 26 47
Ward 28 25 46
Other hospital (excluding ICU) 7 8 1
Other ICU 2 2 1
Type of referral (%)
Medical 52 46 86 < 0.001b
Elective surgery 27 30 7
Emergency surgery 21 24 7
Indication for referral (%)
ICU treatment
ICU 68 69 62 < 0.001b
observatione 32 31 38
a t-test; b chi-square test; c Mann-Whitney test; d from “Requires considerable assistance and frequent medical care” = 50 to “Dead” = 0 ("Normal no complaints;
no evidence of disease” = 100); eIncludes routine admission from theatre.
LOS = length of stay.
Table 2 Length of stay, mortality and cost
Results Overall
population
(n = 7,449)
Accepted
(n =
6,312)
Rejected
(n =
1,137)
P-value
Length of stay (LOS)
Total hospital LOS
- days
Mean (SD) 18.6 (28.0) 19.3
(27.0)
14.7
(32.7)
< 0.001a
Mortality
28-day mortality
(%)
24 22 33 < 0.001b
3-month mortality
(%)
29 28 39 < 0.001b
Cost
Cost per hospital
stay ($)
13,443 14,851 5,629 < 0.001a
Mean (SD) (20,780) (21,597) (12,947)
a t-test; b chi-square test.
Table 3 Results of the mortality analysis
Predicted mortality
Variable ALL
patients
< 5% 5% to
40%
> 40%
Main analysis
Mortality at 28 days 0.7
(0.5 to 0.9)*
1.5
(0.8 to
2.8)
0.7
(0.5 to 1.0)
*
0.6
(0.4 to 0.8)
**
Secondary analysis
Mortality at 3
months
0.7
(0.5 to 1.0)*
1.2
(0.6 to
2.3)
0.8
(0.6 to 1.0)
0.5
(0.3 to 0.8)
**
Predicted mortality at the time of ICU triage based on SAPS II score. Reported
are estimates of the risk of death in accepted versus non-accepted patients
expressed in terms of Odds Ratio, with 95% Confidence Interval. *P < 0.05;
**P < 0.01.
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per life-year saved of $8,121(€6,445) ($1,810 (€1,437)
to $14,432 (€11,454)).
Excluding problematic categories of patients
When excluding patients referred to ICU for observa-
tion (n = 2,363; 32% of the whole sample), 13.9% of the
patients were refused admission. The results for the
effect of ICU admission on mortality at 28 days (0.7;
95% CI: 0.5 to 0.9; P = 0.020) were the same as those in
the main analysis, while the difference in costs between
admitted and non-admitted patients was higher at
$10,409 (€8,261) ($8,479 (€6,729) to $12,340 (€9,794); P
< 0.001). As a consequence, this sensitivity analysis sug-
gests a lower cost effectiveness of ICU admission com-
pared with the main analysis, although the estimates of
the two cost-effectiveness measures became less accu-
rate due to the loss of nearly one third of the sample
size (cost per life saved: $142,806 (€113,338); $57,233
(€45,423) to $228,378 (€181,252); cost per life-year
saved: $9,721 (€7,715); $3,895 (€3,091) to $15,546
(€12,338)).
Results of the sensitivity analysis with exclusion of
terminal cancer patients, defined as patients with diag-
nosis of cancer and Karnofsky ≤50 (n = 220; 3% of the
sample), were substantially the same as those of the
main analysis: cost per life saved: $108,257 (€85,918)
($51,139 (€40,587) to $165,375 (€131,250)); cost per life-
year saved: $7,370 (€5,849) ($3,482 (€2,763) to $11,259
(€8,936)).
Estimating ICU daily cost based on level of care
If the costing method for ICU was modified to account
for the different levels of care received by patients
accepted into ICU, the cost per life saved was $94,898
(€75,316) (95% CI: $24,570 (€19,500) to $165,226
(€131,132)) with a cost per life-year saved of $6,461
(€5,128) (95% CI: $1,673 (€1,328) to $11,249 (€8,928)).
So the different levels of care had minimal effect upon
the costs.
In all sensitivity analyses, similar results were obtained
when considering three-month mortality. The same pat-
tern of cost effectiveness increasing with increasing pre-
dicted mortality was also observed.
Discussion
The widely held view of most health care professionals
is that intensive care is a high cost specialty with
demand exceeding supply. This has effectively led to
rationing [22-27]. An exploratory study in the UK in
1997 examined the mortality among referred patients
who were refused admission [28]. This study concluded
that there was a higher rate of attributable mortality in
patients not admitted, but the authors were not per-
suaded that the solution was to have more beds but
rather clearer guidelines on appropriate admission and
discharge criteria. Studies have found that refusal of
admission to the ICU is common [29], ranging from
38% [22] to 24%, [5]. This may have led to undertreat-
ment or under admission of patients, as illustrated in
chronic obstructive pulmonary disease patients by Wild-
man [30]. In a large proportion the patients who were
not admitted had more severe acute illness, as reflected
by a higher Acute Physiology and Chronic Health Eva-
luation II (APACHE II) score [22]. However, the fre-
quency of admission decreased when the ICU was full
[5] despite the fact that admission to the ICU was asso-
ciated with a lower mortality.
One of the earliest studies to measure cost effective-
ness in the ICU evaluated 211 patient stays in hospitals
in the Paris region [9]. It calculated cost per ICU stay,
cost per life saved and cost per quality adjusted life-year
(QALY) saved. This study concluded that the cost per
life-year saved was $1,150 (€913) and cost per QALY
was $4,100 (€3,254) in 1996. A further prospective study
of 303 consecutive medical ICU patients reported a cost
per life-year saved of 19,330 € ($28,354) [10] in 1998.
However, in both studies patients not admitted were not
investigated and the assumption made that a “do noth-
ing” strategy had a theoretical certainty of death.
Although patients refused admission are more likely to
die, the assumption that a refused admission means cer-
tain death is not sustainable. Patients may be refused
admission on the grounds that treatment is futile or
that they are currently not ill enough to benefit from
ICU therapy more than conventional ward treatments.
For example, in one study [5] the mortality rate for
patients not admitted was 46% and in the other study
[22] the standardised mortality ratio (SMR) for those
admitted was 0.93, whereas the SMR for those triaged
and then refused admission was 1.76. The present study
differed from the previous studies [7-10] in many ways.
The cost effectiveness of admission to intensive care
Table 4 Results of the cost-effectiveness analysis
Predicted mortality
Cost-effectiveness analysis ALL patients < 5% 5% to 40% > 40%
Cost per life saved 103,771
(56,855 to 150,687)
-197,195
(-3,635,418 to 3,241,028)
117,675
(36,241 to 199,109)
60,046
(24,521 to 95,571)
Cost per life-year saved 7,065
(3,871 to 10,259)
-13,426
(-247,510 to 220,658)
8,012
(2,467 to 13,556)
4,088
(1,669 to 6,507)
Estimates of mortality adjusted as in Table 3, and estimates of costs adjusted for the same variables. Reported are costs in $, with 95% CI.
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after ICU triage was assessed by comparing ICU care
with the alternative; that is, ward care. Thus, mortality
and cost of the 6,312 patients admitted to ICU were
compared with those of the 1,347 patients not admitted
to ICU. The number of patients in the present study
was more than 20 times larger, and both medical and
surgical ICU admissions were included in 11 ICUs in 7
different European countries, all with different admis-
sion policies. While not representative of individual
countries, the present results encompass a wide sample.
In addition, the study adjusted for confounding factors
such as age and chronic health status, and the results
were stratified by the severity of acute illness.
In the overall population, the cost per life saved was
$103,771 (€82,358), while the cost per life-year saved
was $7,065 (€5,607), with an average predicted life
expectancy of close to 15 years. These costs fall as pre-
dicted mortality rises, suggesting that intensive care
becomes more cost effective for patients who are
referred to ICU with greater severity of illness. For
patients with more than 40% chance of death, cost per
life saved is about $60,000 (€47,619) and per life-year
saved $4,000 (€3,175).
The cost per life-year saved was derived using an aver-
age figure for life expectancy of about 15 years, which
was based on study individuals’ age, sex, country of ori-
gin (data from the general population) and adjusted for
the initial excess mortality of ICU survivors. This
“excess mortality” was assumed to apply to all the
patients referred for ICU admission, regardless of
whether they were accepted or not. This model assumes
that the excess mortality is associated with the critical
illness, rather than due to adverse effects of the addi-
tional treatments given on ICU. It is important to realise
that the cost-effectiveness estimates reported in this
paper are only valid “on average”, and thus these figures
are not aimed at changing the clinical logic of admitting
or rejecting individual patients. There will always be a
vital clinical decision to make regarding whether a
patient can benefit appropriately from critical care. This
will be highly influenced by the likely survival for the
critical illness itself, the underlying acute illness, chronic
pre-existing medical conditions and other longer term
illness or quality of life factors. Probably the most
important aspect of these results is that they have the
potential to influence the overall funding provision for
critical care facilities and staff.
The figures of cost effectiveness of ICU admission
reported in this study are comparable with or, in some
cases, compare favourably with, those of other interven-
tions. For example, the cost per life-year saved by
screening for breast cancer has been reported as £8,561
(€6,794) in 1996, equivalent to about $12,235 [31], and
that of cervical cancer screening £36,000 (€28,571) per
life saved (reported in 2004) equivalent to $51,450 [32].
The cost per life-year saved of mechanical ventilation
used for life threatening stroke has been reported at
$37,600 (€29,841) [33] in 1996; whereas, the cost per
life-year saved of implantable cardioverter-defibrillators
was $235,000 (€186,508) [34] (reported in 2006). Conse-
quently, ICU treatment seems to be as cost effective as
some other interventions whose cost effectiveness is
more generally accepted. However, our study suggests that
ICU admission of patients with very low predicted mortal-
ity (for example, less than 5%) may be inappropriate both
clinically and economically. It could be argued that
increased critical care provision would lead to a higher
number of admissions with a very low predicted mortality,
which might therefore decrease cost effectiveness. How-
ever, there are reasons to suspect that this might not be
the case. The converse could be true; that it would lead to
an increase in suitable admissions (perhaps by an
increased throughput of major surgery in patients with
some comorbidities) or even a more rapid admission rate
of current patients, so enabling the quicker introduction
of appropriate life saving therapies, some of which are
complex and some of which are relatively simple but are
often delayed on the ordinary ward. This could potentially
lead to an improvement in outcome.
As with every study there are limitations. It could be
argued that a more thorough and consistent study
design would have been to standardise the treatment
received on the ward and on the ICU to ensure that any
inconsistent absence of certain therapies, facilities or
techniques on the ward or the ICU would not have
impacted on survival. However, in the critically ill there
are research ethic difficulties with not assessing the suit-
ability of each patient for a particular type of treatment
or level of escalation of therapy, whether using ward
based or ICU based care. The practicalities of imple-
menting a standard regime on all sites and in all groups
would have been exceptionally difficult, so reducing the
numbers of possible centres or patients even if ethical
issues could be overcome. Therefore, a simpler design
was adopted, that would also avoid the problems of
many subjects refusing to take part, which would have
added its own selection bias.
Because we did not have direct information on term-
inal cancer, we used as a proxy a diagnosis of cancer
together with a poor Karnofsky score. We then per-
formed a sensitivity analysis with exclusion of these
patients, which showed results very similar to those of
the main analysis. Although the use of this proxy may
have caused the wrong inclusion of some cancer
patients who were not terminal but had low Karnofsky
scores due to other severe comorbidities, this sensitivity
analysis would have detected substantial bias if there
were any.
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The major limitation of this study is inherent to its
observational nature, where the decision to accept a
patient into ICU or not is influenced by factors asso-
ciated with the outcome of the patient. Although we
adjusted the analyses for important confounding factors,
including measures of severity of illness, residual con-
founding is likely to be present. Moreover, we used a
top-down approach to the costing of ICU and ward,
while ideally the costing method should be bottom up
(microcosting), where the individual items of cost are
accounted for, and totalled. This method, however, is too
expensive to be currently viable throughout Europe. The
fact that the use of an alternative and more sensitive
approach to costing the ICU stay, based on the level of
care received by the patient, did not modify our results
suggests robustness of the findings. It is also reassuring
to see that our estimate of an average daily ICU cost in
the 11 centres using a top-down approach of €1,028 is
indeed close to the figure of €923 found in 51 ICUs in
German teaching hospitals obtained by Moerer et al. [35]
through the use of a bottom-up approach.
Conclusions
It has been widely assumed that ICU care is expensive
and this has almost certainly encouraged an unreason-
ably low level of provision of ICU beds and resources.
The average cost per life saved of $103,771 (€82,358)
and an average cost per life-year gained of $7,065
(€5,607) observed in our study would suggest that this
assumption is incorrect. This information is important
for health care providers who need to balance the costs
and benefits of ICU against those of other types of
health care. Our results may also influence those who
sanction the construction of critical care facilities in the
future and may allow those who manage critical care to
argue more effectively that critical care potentially does
represent value for money and should have a similar
priority to other therapies where a higher level of finan-
cial provision is regarded as the norm.
Key messages
• The daily cost of intensive care has been described,
but randomised controlled studies to assess cost
effectiveness of admission to intensive care are unli-
kely to be feasible.
• Observational studies looking at the cost effective-
ness of admission to intensive care after ICU triage
have generally assumed that the result of non-admis-
sion would be death, but some patients do survive.
• This observational study attempts to determine
cost effectiveness for intensive care admission by
observing patients who are admitted or refused
admission to intensive care.
• The findings of this study suggest that ICU admis-
sion is cost effective, with cost per life saved and per
life-year saved comparable to, or less than, estab-
lished therapies used elsewhere in medicine.
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per patient based on level of care.
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